By Chris Wack

 

Evotec SE on Friday said Bayer AG is discontinuing the development of the investigational P2X3 receptor antagonist eliapixant, which stems from a former joint company multitarget research alliance.

Evotec said that following a review of the available data, Bayer concluded the overall benefit no longer outweighs the risk in the actively pursued indications.

Evotec said it regains the rights to all P2X3 assets. The company said it will evaluate the underlying data once available and consider all options.

Evotec shares fell 10% to $18.50 in premarket trading.

 

Write to Chris Wack at chris.wack@wsj.com

 

(END) Dow Jones Newswires

February 04, 2022 08:22 ET (13:22 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Bayer Charts.
Bayer (TG:BAYN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Bayer Charts.